JP2019517464A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517464A5 JP2019517464A5 JP2018560068A JP2018560068A JP2019517464A5 JP 2019517464 A5 JP2019517464 A5 JP 2019517464A5 JP 2018560068 A JP2018560068 A JP 2018560068A JP 2018560068 A JP2018560068 A JP 2018560068A JP 2019517464 A5 JP2019517464 A5 JP 2019517464A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvates
- acceptable salts
- selection
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 5
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 3
- 201000011190 diabetic macular edema Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010019860 Hereditary angioedema Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000001399 Kallikrein Human genes 0.000 claims 1
- 108060005987 Kallikrein Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 239000005862 Whey Substances 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021080175A JP7109012B2 (ja) | 2016-05-31 | 2021-05-11 | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662343363P | 2016-05-31 | 2016-05-31 | |
| GBGB1609517.6A GB201609517D0 (en) | 2016-05-31 | 2016-05-31 | Enzyme inhibitors |
| GB1609517.6 | 2016-05-31 | ||
| US62/343,363 | 2016-05-31 | ||
| US201762456219P | 2017-02-08 | 2017-02-08 | |
| US62/456,219 | 2017-02-08 | ||
| GB1702044.7 | 2017-02-08 | ||
| GBGB1702044.7A GB201702044D0 (en) | 2017-02-08 | 2017-02-08 | Enzyme inhibitors |
| PCT/GB2017/051546 WO2017207983A1 (en) | 2016-05-31 | 2017-05-31 | Pyrazole derivatives as plasma kallikrein inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021080175A Division JP7109012B2 (ja) | 2016-05-31 | 2021-05-11 | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517464A JP2019517464A (ja) | 2019-06-24 |
| JP2019517464A5 true JP2019517464A5 (cg-RX-API-DMAC7.html) | 2020-07-09 |
| JP6884801B2 JP6884801B2 (ja) | 2021-06-09 |
Family
ID=60478506
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560068A Expired - Fee Related JP6884801B2 (ja) | 2016-05-31 | 2017-05-31 | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
| JP2021080175A Active JP7109012B2 (ja) | 2016-05-31 | 2021-05-11 | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021080175A Active JP7109012B2 (ja) | 2016-05-31 | 2021-05-11 | 血漿カリクレインインヒビターとしてのピラゾール誘導体 |
Country Status (32)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| SMT202000382T1 (it) | 2016-05-31 | 2020-09-10 | Kalvista Pharmaceuticals Ltd | Derivati di pirazolo come inibitori di callicreina plasmatica |
| GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719882D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
| PL3716952T3 (pl) | 2017-11-29 | 2022-05-02 | Kalvista Pharmaceuticals Limited | Postacie dawkowania zawierające inhibitor kalikreiny osoczowej |
| GB201719881D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| TW201925188A (zh) * | 2017-11-29 | 2019-07-01 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| CN112839711A (zh) * | 2018-10-10 | 2021-05-25 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| CN114728962B (zh) | 2019-09-18 | 2025-09-19 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
| US11370803B2 (en) | 2019-09-18 | 2022-06-28 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TWI873290B (zh) | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| CN115210230A (zh) * | 2020-03-04 | 2022-10-18 | 南京明德新药研发有限公司 | 杂环类化合物 |
| KR20230024981A (ko) * | 2020-06-16 | 2023-02-21 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
| WO2022056051A1 (en) * | 2020-09-10 | 2022-03-17 | Merck Sharp & Dohme Corp. | Plasma kallikrein inhibitors |
| TW202228686A (zh) | 2020-10-15 | 2022-08-01 | 英商卡爾維斯塔製藥有限公司 | 血管性水腫之治療 |
| WO2022172006A1 (en) | 2021-02-09 | 2022-08-18 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| CN117396474A (zh) | 2021-03-17 | 2024-01-12 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂 |
| WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| CN116003386B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途 |
| WO2025153806A1 (en) | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
| US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| CA2463975A1 (en) | 2001-10-26 | 2003-05-01 | Maria Emilia Di Francesco | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| MXPA04010622A (es) | 2002-04-26 | 2005-01-25 | Lilly Co Eli | Derivados de triazol como antagonistas de receptor de taquicinina. |
| EP1426364A1 (en) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Imidazole-derivatives as factor Xa inhibitors |
| DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| EP2308848A1 (en) | 2003-02-03 | 2011-04-13 | Janssen Pharmaceutica NV | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| PL1784402T3 (pl) | 2004-09-03 | 2011-12-30 | Yuhan Corp | Pochodne pirolo[3,2-c]pirydyny oraz sposoby ich wytwarzania |
| US8841259B2 (en) | 2005-02-24 | 2014-09-23 | Joslin Diabetes Center | Compositions and methods for treating vascular permeability |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
| US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| BRPI0714062A2 (pt) | 2006-07-06 | 2012-12-18 | Glaxo Group Ltd | n-fenil-metil-5-oxo-prolina-2-amidas substituìdas como antagonistas do receptor da p2x, e os seus métodos de uso |
| CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| AU2007341232B2 (en) | 2006-12-29 | 2013-01-31 | AbbVie Deutschland GmbH & Co. KG | Carboxamide compounds and their use as calpain inhibitors |
| WO2008091692A2 (en) | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
| MX2009009540A (es) | 2007-03-07 | 2009-09-16 | Alantos Pharm Holding | Inhibidores de metaloproteasa que contienen una porcion heterociclica. |
| JP5427769B2 (ja) | 2007-03-30 | 2014-02-26 | サノフイ | Ｐｇｄｓ阻害剤としてのピリミジンヒドラジド化合物 |
| KR20090127435A (ko) | 2007-04-03 | 2009-12-11 | 글락소 그룹 리미티드 | Ｐ2ｘ7 조절제로서의 이미다졸리딘 카르복스아미드 유도체 |
| JP5390520B2 (ja) | 2007-07-26 | 2014-01-15 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 新規殺菌剤 |
| AU2008288897A1 (en) | 2007-08-22 | 2009-02-26 | Allergan, Inc. | Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009083553A1 (en) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
| WO2009097141A1 (en) | 2008-01-31 | 2009-08-06 | Joslin Diabetes Center | Methods for treatment of kallikrein-related disorders |
| WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| MX2011000044A (es) | 2008-07-08 | 2011-02-22 | Daiichi Sankyo Co Ltd | Compuesto heterociclilo aromatico que contiene nitrogeno. |
| US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| MX2012006913A (es) | 2009-12-18 | 2012-08-23 | Activesite Pharmaceuticals Inc | Profarmacos de inhibidores de calicreina plasmatica. |
| JP2011157349A (ja) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 |
| EA022121B1 (ru) | 2010-01-28 | 2015-11-30 | Зе Медисинс Компани (Лейпциг) Гмбх | Ингибиторы трипсиноподобных сериновых протеаз, их получение и применение |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
| WO2012009009A2 (en) | 2010-07-14 | 2012-01-19 | Addex Pharma S.A. | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| EP2458315B1 (de) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2012174362A1 (en) | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| US9249096B2 (en) | 2011-09-27 | 2016-02-02 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| WO2013048982A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| WO2013111108A1 (en) * | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| EP2812001B1 (en) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9846160B2 (en) | 2012-02-27 | 2017-12-19 | Board Of Regents, The University Of Texas Systems | Ganglioside GD2 as a marker and target on cancer stem cells |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| US9045486B2 (en) | 2013-01-08 | 2015-06-02 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| EP3456744B1 (en) | 2013-01-20 | 2023-03-29 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| BR112015022340A2 (pt) | 2013-03-15 | 2017-07-18 | Verseon Corp | método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica |
| PT3305778T (pt) | 2013-05-23 | 2022-05-02 | Kalvista Pharmaceuticals Ltd | Inibidores de calicreína plasmática |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| HUE14755117T2 (hu) | 2013-08-14 | 2018-12-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorok |
| BR112016015449A8 (pt) | 2013-12-30 | 2020-06-09 | Lifesci Pharmaceuticals Inc | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| KR102510427B1 (ko) | 2014-03-07 | 2023-03-14 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| US9695166B2 (en) | 2014-05-05 | 2017-07-04 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| WO2015171526A2 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Tricyclic pyrazolopyridine compounds |
| AU2015289643B2 (en) | 2014-07-16 | 2020-10-22 | Attune Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| DK3182962T3 (da) | 2014-08-22 | 2023-09-18 | Biocryst Pharm Inc | Compositions and uses of amidine derivatives |
| MX2017003624A (es) | 2014-09-17 | 2017-07-13 | Verseon Corp | Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas. |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| LT3261639T (lt) | 2015-02-27 | 2022-11-25 | Verseon International Corporation | Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai |
| CA2991174A1 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| EP3317259A4 (en) | 2015-07-01 | 2019-06-12 | Lifesci Pharmaceuticals, Inc. | THERAPEUTIC INHIBITING COMPOUNDS |
| EP3368529B1 (en) | 2015-10-27 | 2022-04-06 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| WO2017072021A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
| SMT202000382T1 (it) | 2016-05-31 | 2020-09-10 | Kalvista Pharmaceuticals Ltd | Derivati di pirazolo come inibitori di callicreina plasmatica |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| CN110022875A (zh) | 2016-07-11 | 2019-07-16 | 莱福斯希医药公司 | 治疗性抑制化合物 |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
| TW201925188A (zh) | 2017-11-29 | 2019-07-01 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
-
2017
- 2017-05-31 SM SM20200382T patent/SMT202000382T1/it unknown
- 2017-05-31 LT LTEP17728593.9T patent/LT3464271T/lt unknown
- 2017-05-31 ME MEP-2020-150A patent/ME03794B/me unknown
- 2017-05-31 PT PT177285939T patent/PT3464271T/pt unknown
- 2017-05-31 EP EP17728593.9A patent/EP3464271B1/en active Active
- 2017-05-31 CN CN202110792609.7A patent/CN113387933A/zh active Pending
- 2017-05-31 SG SG10201913616UA patent/SG10201913616UA/en unknown
- 2017-05-31 HU HUE17728593A patent/HUE049918T2/hu unknown
- 2017-05-31 HR HRP20201131TT patent/HRP20201131T1/hr unknown
- 2017-05-31 US US16/301,192 patent/US11180484B2/en not_active Expired - Fee Related
- 2017-05-31 EP EP20173514.9A patent/EP3760622A1/en not_active Withdrawn
- 2017-05-31 IL IL293304A patent/IL293304A/en unknown
- 2017-05-31 JP JP2018560068A patent/JP6884801B2/ja not_active Expired - Fee Related
- 2017-05-31 SI SI201730324T patent/SI3464271T1/sl unknown
- 2017-05-31 DK DK17728593.9T patent/DK3464271T3/da active
- 2017-05-31 BR BR112018074395-0A patent/BR112018074395A2/pt not_active Application Discontinuation
- 2017-05-31 MX MX2018014188A patent/MX384624B/es unknown
- 2017-05-31 AU AU2017275820A patent/AU2017275820B2/en not_active Ceased
- 2017-05-31 RS RS20200866A patent/RS60600B1/sr unknown
- 2017-05-31 RU RU2020140891A patent/RU2020140891A/ru unknown
- 2017-05-31 IL IL263235A patent/IL263235B/en unknown
- 2017-05-31 MD MDE20190408T patent/MD3464271T2/ro not_active IP Right Cessation
- 2017-05-31 SG SG11201809922YA patent/SG11201809922YA/en unknown
- 2017-05-31 KR KR1020187038212A patent/KR102424709B1/ko active Active
- 2017-05-31 WO PCT/GB2017/051546 patent/WO2017207983A1/en not_active Ceased
- 2017-05-31 KR KR1020227025232A patent/KR20220107319A/ko not_active Withdrawn
- 2017-05-31 CA CA3025718A patent/CA3025718A1/en active Pending
- 2017-05-31 UA UAA201811720A patent/UA123735C2/uk unknown
- 2017-05-31 ES ES17728593T patent/ES2805027T3/es active Active
- 2017-05-31 PL PL17728593T patent/PL3464271T3/pl unknown
- 2017-05-31 RU RU2018141881A patent/RU2739447C2/ru active
- 2017-05-31 CN CN201780034028.9A patent/CN109311847B/zh not_active Expired - Fee Related
-
2018
- 2018-11-08 PH PH12018502355A patent/PH12018502355A1/en unknown
- 2018-11-12 CL CL2018003213A patent/CL2018003213A1/es unknown
- 2018-11-16 MX MX2021008342A patent/MX2021008342A/es unknown
- 2018-11-28 CO CONC2018/0012894A patent/CO2018012894A2/es unknown
- 2018-12-20 ZA ZA2018/08639A patent/ZA201808639B/en unknown
- 2018-12-28 EC ECSENADI201894983A patent/ECSP18094983A/es unknown
-
2020
- 2020-08-06 CY CY20201100735T patent/CY1123223T1/el unknown
-
2021
- 2021-01-12 AU AU2021200140A patent/AU2021200140B2/en not_active Ceased
- 2021-05-11 JP JP2021080175A patent/JP7109012B2/ja active Active
- 2021-05-20 PH PH1/2021/552497A patent/PH12021552497A1/en unknown
- 2021-09-21 US US17/480,424 patent/US20220002275A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517464A5 (cg-RX-API-DMAC7.html) | ||
| HRP20210350T1 (hr) | Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao inhibitori plazmatskog kalikreina | |
| HRP20201131T1 (hr) | Derivati pirazola kao inhibitori kalikreina plazme | |
| JP2015528798A5 (cg-RX-API-DMAC7.html) | ||
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| HRP20221019T1 (hr) | Polimorfi od n-[(3-fluoro-4-metoksipiridin-2-il)metil]-3-(metoksimetil)-1-({4-[2-oksopiridin-1-il)metil]fenil}metil)pirazol-4-karboksamida kao kalikrein inhibitori | |
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2019517463A5 (cg-RX-API-DMAC7.html) | ||
| JP2016505637A5 (cg-RX-API-DMAC7.html) | ||
| JP2021504310A5 (cg-RX-API-DMAC7.html) | ||
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| FI3811943T3 (fi) | Yhdiste käytettäväksi silmäsairauksien hoidossa | |
| ME00591B (me) | Upotreba dii4 antagonista kod ishemijske povrede ili vaskularne insuficijencije | |
| JP2016510326A5 (cg-RX-API-DMAC7.html) | ||
| JP2017520527A5 (cg-RX-API-DMAC7.html) | ||
| JP2017516860A5 (cg-RX-API-DMAC7.html) | ||
| JP2014506582A5 (cg-RX-API-DMAC7.html) | ||
| JP2020536919A5 (cg-RX-API-DMAC7.html) | ||
| RU2012134639A (ru) | Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза | |
| MX2024002863A (es) | Medicina para la prevencion y tratamiento de enfermedades vinculadas a la actividad antiobesidad. | |
| JP2017522300A5 (cg-RX-API-DMAC7.html) | ||
| JP2015531397A5 (cg-RX-API-DMAC7.html) | ||
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| UA122336C2 (uk) | Бісамідна похідна дикарбонової кислоти як засіб, що стимулює регенерацію тканин і відновлення знижених функцій тканин | |
| RU2013107659A (ru) | ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε |